| Literature DB >> 26041300 |
Kevin O Saunders, Lingshu Wang, M Gordon Joyce, Zhi-Yong Yang, Alejandro B Balazs, Cheng Cheng, Sung-Youl Ko, Wing-Pui Kong, Rebecca S Rudicell, Ivelin S Georgiev, Lijie Duan, Kathryn E Foulds, Mitzi Donaldson, Ling Xu, Stephen D Schmidt, John-Paul Todd, David Baltimore, Mario Roederer, Ashley T Haase, Peter D Kwong, Srinivas S Rao, John R Mascola, Gary J Nabel.
Abstract
Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates and may slow the spread of human immunodeficiency virus type 1 (HIV-1). Although protection by passive transfer of human bnAbs has been demonstrated in monkeys, durable expression is essential for its broader use in humans. Gene-based expression of bnAbs provides a potential solution to this problem, although immune responses to the viral vector or to the antibody may limit its durability and efficacy. Here, we delivered an adeno-associated viral vector encoding a simianized form of a CD4bs bnAb, VRC07, and evaluated its immunogenicity and protective efficacy. The expressed antibody circulated in macaques for 16 weeks at levels up to 66 g/ml, although immune suppression with cyclosporine (CsA) was needed to sustain expression. Gene-delivered simian VRC07 protected against simian-human immunodeficiency virus (SHIV) infection in monkeys 5.5 weeks after treatment. Gene transfer of an anti-HIV antibody can therefore protect against infection by viruses that cause AIDS in primates when the host immune responses are controlled.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26041300 PMCID: PMC4524228 DOI: 10.1128/JVI.00908-15
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103